U.S. Markets closed

TG Therapeutics (TGTX) in Focus: Stock Moves 8.6% Higher

Zacks Equity Research
1 / 2

Material ETFs Gain on Q3 Earnings

Given the solid results, the material sector is up 2.5% in response to earnings announcements. The positive trading has also pushed material ETFs higher over the past month.

TG Therapeutics, Inc. TGTX was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 54.8% in the past one-month time frame.

The move came after the company reported that its final Phase2 Multiple Sclerosis data were accepted for presentation at the upcoming 34th Congress of ECTRIMS.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

TG Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  

TG Therapeutics, Inc. Price

TG Therapeutics, Inc. Price | TG Therapeutics, Inc. Quote

A better-ranked stock in the Medical – Products industry is ICU Medical, Inc. ICUI, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is TGTX going up? Or down? Predict to see what others think: Up or Down

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICU Medical, Inc. (ICUI) : Free Stock Analysis Report
TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research